Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month High – Should You Buy?

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $47.34 and last traded at $47.9380, with a volume of 57363 shares traded. The stock had previously closed at $45.52.

Analyst Ratings Changes

ORKA has been the subject of several research reports. Barclays increased their price target on shares of Oruka Therapeutics from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, March 13th. UBS Group started coverage on shares of Oruka Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research report on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. Finally, Guggenheim reaffirmed a “buy” rating and issued a $60.00 price target on shares of Oruka Therapeutics in a report on Friday, March 13th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Oruka Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $59.60.

Oruka Therapeutics Stock Performance

The company has a market cap of $2.33 billion, a P/E ratio of -25.26 and a beta of -0.38. The stock has a 50-day moving average of $35.59 and a two-hundred day moving average of $29.73.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.16. As a group, sell-side analysts forecast that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the transaction, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joana Goncalves sold 7,641 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $40.91, for a total value of $312,593.31. Following the completion of the transaction, the insider directly owned 33,377 shares of the company’s stock, valued at approximately $1,365,453.07. This trade represents a 18.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 23,765 shares of company stock worth $849,575 in the last 90 days. 24.69% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds have recently modified their holdings of the stock. Fairmount Funds Management LLC increased its stake in Oruka Therapeutics by 9.9% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock worth $71,252,000 after acquiring an additional 333,340 shares during the last quarter. Avoro Capital Advisors LLC purchased a new position in shares of Oruka Therapeutics in the third quarter valued at $25,640,000. Financial Enhancement Group LLC purchased a new position in shares of Oruka Therapeutics in the third quarter valued at $631,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Oruka Therapeutics in the third quarter worth $296,000. Finally, B Group Inc. raised its stake in Oruka Therapeutics by 28.8% during the second quarter. B Group Inc. now owns 75,000 shares of the company’s stock valued at $841,000 after purchasing an additional 16,785 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.